The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

Various preclinical and a limited number of clinical studies of CAR-NK cells have shown
promising results: efficient elimination of target cells without side effects similar to CAR-T …

Sorafenib is an anti-tumor drug widely used in clinical treatment, which can inhibit tyrosine
kinase receptor on cell surface and serine/threonine kinase in downstream Ras/MAPK …

Ferroptosis is potential to relieve drug resistance in hepatocellular carcinoma (HCC).
Glutathione peroxidase 4 (GPX4) is a critical modulator of ferroptosis. This study discussed …

Sorafenib, FDA-approved therapy for patients with advanced hepatocellular carcinoma
(HCC), leads to limited improvement in overall survival. However, it may indirectly impact the …

Background Heterogeneity of hepatocellular carcinoma (HCC) presents significant
challenges for therapeutic strategies and necessitates combinatorial treatment approaches …

Hollow mesoporous silica nanoparticles (HMSNs) are considered appealing nanovehicles
for drug delivery due to their exceptional drug loading and release potential. This study …

Background Chromatin organization is associated with tumorigenesis; however, information
on its role in hepatocellular carcinoma (HCC) is limited. Moreover, although immune …

Background Hepatocellular carcinoma (HCC) is a common liver malignancy with limited
treatment options. Previous studies expressed the potential synergy of sorafenib and NK cell …

Introduction Hepatocellular carcinoma (HCC) remains a major clinical problem as more than
half of these cases recur after radical resection. Natural killer (NK) cells are at the forefront of …